Synaps

Developing novel photodynamic therapies for neurosurgery

Synaps
  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

publications

5-ALA Photodynamic Therapy in Neurosurgery, Towards the Design of a Treatment Planning System: A Proof of Concept

2/1/2017

 
Dupont C, Betrouni N, Mordon S, Reyns N, Vermandel M.
5-ALA Photodynamic Therapy in Neurosurgery, Towards the Design of a Treatment Planning System: A Proof of Concept
IRBM, 2017. 38(1): p. 34-41.

ABSTRACT

Purpose: Glioblastoma (GBM) treatment still remains a complex challenge. Among alternatives or adjuvant therapies, photodynamic therapy (5-ALA PDT) appears to be a promising approach. 5-ALA PDT can be delivered intraoperatively, early after tumor resection, or interstitially according to brain tumor location. A treatment planning system was designed to manage dosimetry issues before PDT delivery.

Methods: The TPS was developed according to a specific workflow from stereotactic image registration to light fluence rate modeling. Here, we describe a proof of concept of a treatment planning system (TPS) dedicated to interstitial 5-ALA PDT. This tool enables the planning of a whole treatment in surgical stereotactic conditions. Stereotactic registration and dosimetry components are detailed and evaluated. The registration process is compared to a commercial solution (Leksell Gamma Plan®, Elekta®, Sweden) defined as the ground truth and dosimetry model implemented in our TPS and is compared to numerical simulations.

Results: Registration achieved a sub-millimetric mean relative error that matched the standard MRI resolution. Dosimetry comparison showed a negligible error between analytical and numerical models and enabled a validation of the dosimetry algorithm implemented.

Conclusions: A treatment planning system was designed to achieve 5-ALA PDT simulations before the patients underwent surgery. Similarly, for radiation therapy, we proposed a system to plan and evaluate the 5-ALA PDT dosimetry for optimizing treatment delivery. Although this system remains to be perfected, this preliminary work aimed to demonstrate the feasibility of planning 5-ALA PDT treatments in stereotactic conditions. Future improvements will mainly focus on the optimization of the treatment delivery, automatic segmentation and GPU-accelerated Monte-Carlo management to take into account GBM tissue heterogeneity.

DOI: 10.1016/j.irbm.2016.11.002

ScienceDirect Link | HAL Link

Comments are closed.
Université Lille 2
Onco Thai
Inserm
CHRU Lille
Picture
 Legal notice - Credits